GNRH1 and prostate adenocarcinoma: These studies clearly demonstrated that chronic administration of the agonist [d-Trp6]-LH-RH inhibits the growth of Dunning prostate adenocarcinoma, a well-documented androgen-dependent prostate cancer10,11.